Cargando…
Immune checkpoint inhibitor-mediated colitis is associated with cancer overall survival
BACKGROUND: Immune checkpoint inhibitor-mediated colitis (IMC) is a common adverse event following immune checkpoint inhibitor (ICI) therapy for cancer. IMC has been associated with improved overall survival (OS) and progression-free survival (PFS), but data are limited to a single site and predomin...
Autores principales: | Weingarden, Alexa R, Gubatan, John, Singh, Sundeep, Balabanis, Tatiana Clorice, Patel, Akshar, Sharma, Arpita, Habtezion, Aida |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9627421/ https://www.ncbi.nlm.nih.gov/pubmed/36338892 http://dx.doi.org/10.3748/wjg.v28.i39.5750 |
Ejemplares similares
-
Disease exacerbation is common in inflammatory bowel disease patients treated with immune checkpoint inhibitors for malignancy
por: Rubin, Samuel J S, et al.
Publicado: (2022) -
SARS-CoV-2 Testing, Prevalence, and Predictors of COVID-19 in Patients with Inflammatory Bowel Disease in Northern California
por: Gubatan, John, et al.
Publicado: (2020) -
Immune checkpoint inhibitor-mediated colitis in gastrointestinal malignancies and inflammatory bowel disease
por: Weingarden, Alexa R, et al.
Publicado: (2021) -
1162: SINGLE-CELL IMMUNE PROFILING AND REPERTOIRE ANALYSIS OF CONVALESCENT PATIENTS WITH INFLAMMATORY BOWEL DISEASE AND SARS-COV-2 ANTIBODY RESPONSE
por: Gubatan, John Mark, et al.
Publicado: (2022) -
Artificial intelligence applications in inflammatory bowel disease: Emerging technologies and future directions
por: Gubatan, John, et al.
Publicado: (2021)